Inventisbio 益方生物
11 significant filings since 31 May 2026: 11 on equity incentive. The latest, on 22 Aug 2026: 君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划预留授予部分第三个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书.
自 31 May 2026 起有 11 份重大公告：equity incentive 11 份。最新一份（22 Aug 2026）：君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2022年限制性股票激励计划预留授予部分第三个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 1 broker | 1 broker |
| 7 days ago | 1 broker | 1 broker |
| 30 days ago | 2 brokers | 2 brokers |
| 60 days ago | -0.39 | -0.19 |
| 90 days ago | -0.39 | -0.19 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus was -0.39 in both May 2026 and Jul 2026. The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 0 ▼ 0 = 0 | ▲ 0 ▼ 0 = 0 |
| Last 90 days | ▲ 0 ▼ 0 = 1 | ▲ 0 ▼ 0 = 1 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 0. 惊喜幅度需公告前120天内至少3家券商预测；FY2025仅0家；FY2024仅0家。